The phase III EMERALD study found that when used as a monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer, elacestrant significantly improved progression-free survival in the overall population and in patients with tumors harboring estrogen receptor 1 mutations, compared to the standard of care.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
